Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:translations:french [06.11.2018]
sallieq [Contexte et justification scientifique pour le traitement]
home:translations:french [05.10.2019] (current)
sallieq [Data]
Line 292: Line 292:
     * Signes de la résolution sur l'​inflammation CT et IRM     * Signes de la résolution sur l'​inflammation CT et IRM
    
 +
    
 =====  Arrêt du Protocole ===== =====  Arrêt du Protocole =====
Line 311: Line 312:
    
 Les patients qui cessent de l'​olmésartan se terminent leur rétablissement. Les patients qui cessent de l'​olmésartan se terminent leur rétablissement.
 +
 +===== Data =====
 +
 +[[home:​patients:​cohort_statistics#​later_information_2013|Success rates for various Dx, compiled in 2013]]
    
  
 +[[home:​food:​aim_health:​aging|Olmesartan research]]
 +
 +==== Response in 5 diagnoses ====
 +
 + ​TOTALS:​ 864 members;573 report success; 119 report no success; and for 172 results are not clear.
 +
 +SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
 +
 +Sarcoidosis success 75.8%
 +
 +Chronic Fatigue Syndrome success 60.1%
 +
 +Lyme disease success 66.9%
 +
 +Rheumatoid arthritis success 69.2%
 +
 +Fibromyalgia success 64.2%
 +
 +All Other Th1 disease success 59.8% 
 ===== Notes and comments ===== ===== Notes and comments =====
  
home/translations/french.1528690598.txt.gz · Last modified: 06.11.2018 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.